DURHAM, N.C., United States and BEIJING, China – June 30, 2022 – Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced its participation in the following conference in July 2022. Details of the conference and management presentations are as follows:

SinoLink Securities Investor Conference

Participants: Management team and IR
For more information, please contact your SinoLink Securities representative.

Industrial Securities 2022 Interim Conference

Investor Meetings: July 6, 2022
Participants: Management team and IR
For more information, please contact your Industrial Securities representative.

About Brii Bio

Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide. For more information, visit www.briibio.com.

Media Inquiry:
media@briibio.com
Summer Li (China)
+86-135-2191-1607
Ben Shannon (U.S.)
+1-919-360-3039

Investor Inquiry:
ir@briibio.com
Chris Fang
+86-139-1692-8049